ROIC has oscillated in a narrow 6.1%-7.3% band across eight of the last ten quarters, with the two outliers (2.2% in 2024Q4 and 2025Q2) reflecting the same earnings dislocations that distorted margins in the prior income statement work, so the underlying return on invested capital looks stable rather than improving. Asset turnover of roughly 0.30-0.34 has been the binding constraint, meaning the ROIC recovery since 2025Q2 appears driven by margin normalization rather than better asset productivity. For an industrial compounding on a $230B backlog, a mid-single-digit ROIC spread over an estimated cost of capital warrants scrutiny, and investors should monitor whether the F-35 ramp finally lifts turnover above the 0.34 ceiling it has tested four times.

The deleveraging path is notable: debt-to-equity has declined in each of the last four quarters from 4.06 to 2.04, and debt-to-EBITDA has roughly halved from 18.86 to 7.15, which reads more like EBITDA recovery and equity retention from the buyback pause than outright debt retirement. Coverage at 9.23x now sits comfortably above the 6.28x-8.60x range seen through most of 2024-2025, but the 2025Q2 collapse to 2.52x shows how quickly a program charge can compress the cushion when leverage is above 4x. Even at 2.04, the ratio remains elevated versus Northrop Grumman at 1.18 and General Dynamics at 0.38, so a recurrence of the cost-plus-to-fixed-price margin pressure noted in prior analysis could re-test coverage far faster than the current run-rate implies.

With DPO fixed in a tight 14-25 day band and DIO stable at 17-22 days, virtually all of the cycle volatility traces to DSO, which is consistent with the lumpy cash-flow dynamics of percentage-of-completion billing and Foreign Military Sales milestone payments rather than any change in operating efficiency. The 10-day cycle recorded in 2026Q3 alongside a 14-day DSO should therefore be read as a timing artifact, not evidence of a structural working capital improvement, especially since the same metric printed 86 days one quarter earlier. Asset turnover near 0.33 is unchanged over ten quarters, implying that the record backlog has not yet translated into higher asset productivity and that the cash conversion gains seen recently may reverse on a similar billing schedule.

The 30% discount between trailing and forward P/E appears to require sustained delivery of the 10%+ revenue growth seen in recent quarters, so the gap is less a cheapness signal than an embedded expectation that the record $230B backlog converts on schedule. On EV/EBITDA, LMT's 18.59 sits above Northrop Grumman at 16.29 and General Dynamics at 16.89 but below RTX at 21.17, a positioning that looks defensible given its accelerating growth yet leaves limited room for another cumulative catch-up adjustment of the 2025Q2 variety. The P/B of 20.85 is largely an artifact of a compressed equity base rather than a rich asset valuation, and the 2.2% dividend yield offers only modest downside support if forward estimates fail to materialize.

The ROIC gap alongside a superior 8.9% net margin versus RTX at 7.6% and L3Harris at 7.3% suggests LMT's issue is capital intensity and asset turnover rather than pricing power, which is coherent with a heavy Aeronautics mix dominated by low-margin platform production. Leverage is the clearest structural divergence: at 2.04 versus 0.38-1.18 for GD, NOC and RTX, LMT looks more like a company funding shareholder returns with debt than peers funding them with retained earnings, echoing the buyback-pause dynamics already observed. Whether this gap proves structural or temporary likely turns on whether the munitions and missile-defense mix at MFC expands enough to lift ROIC toward the peer range without requiring additional balance sheet capacity.